Shandong Boan Doses First Subject in Phase I Trial of BA1203 – World’s Only PD‑1/IL‑2 Antibody‑Cytokine Prodrug Advancing in Advanced Solid Tumors

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first subject has been enrolled in the Phase I clinical trial in China of BA1203, an investigational anti‑PD‑1/IL‑2 antibody‑cytokine prodrug for patients with advanced solid tumors – marking the clinical debut of what the company describes as the world’s only PD‑1/IL‑2 molecule combining high IL‑2α receptor activity, an IL‑2 masking design and PD‑1‑blocking activity.

Trial Initiation

Drug Profile & Mechanism of Action

• Molecule: BA1203 – an anti‑PD‑1/IL‑2 antibody‑cytokine prodrug that fuses the mechanisms of action of a PD‑1 antibody and an IL‑2 cytokine into a single engineered molecule.
• First‑in‑Class Positioning: Currently the world’s only PD‑1/IL‑2 molecule that combines high activity at the IL‑2α receptor with an IL‑2 masking design and PD‑1‑blocking activity.
• Tumor‑Selective Activation: Through its IL‑2 masking prodrug design, BA1203 is intended to selectively activate IL‑2 within the tumor microenvironment while maintaining lower IL‑2 activity in peripheral tissues – enhancing local antitumor immunity and reducing the risk of systemic toxicity, the historic limitation of systemic IL‑2 therapy.
• Precise Immune Targeting: A high‑affinity, bivalent PD‑1‑targeting design strengthens checkpoint blockade and facilitates the precise delivery of IL‑2 to PD‑1‑positive tumor‑infiltrating T cells, concentrating cytokine stimulation exactly where antitumor immunity is generated.
• Dual Mechanism Rationale: By pairing checkpoint inhibition with conditional cytokine agonism, BA1203 aims to convert immunologically “cold” tumors responsive – addressing a core resistance mechanism in patients who progress on existing PD‑1 monotherapies.

Clinical Development – Phase I Study

The multicenter, open‑label Phase I trial is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BA1203 in patients with advanced solid tumors. As a first‑in‑human study, it will establish the dose‑escalation profile of the prodrug construct and provide early signals of tumor‑microenvironment‑selective IL‑2 activation. Dose levels, cohort structure, site count and enrollment targets were not disclosed.

Market Impact & Outlook

• Next‑Generation IO Landscape: With PD‑1 monotherapy response rates plateauing across solid tumors, combination and cytokine‑fusion approaches represent the industry’s principal avenue for expanding checkpoint‑inhibitor benefit – placing BA1203 in a strategically critical modality class.
• IL‑2 Revival via Masking Technology: Cytokine masking/prodrug designs aim to solve the narrow therapeutic window that has historically confined high‑dose IL‑2 to specialized inpatient settings; a tumor‑activated IL‑2 delivered on a PD‑1 backbone could broaden outpatient applicability.
• Differentiation: The bivalent PD‑1 targeting plus conditional IL‑2α activity combination is described as unique worldwide, potentially supporting both domestic first‑mover positioning and global partnering interest.
• Boan’s Pipeline Momentum: The first‑subject milestone advances Boan Biotechnology’s clinical portfolio in oncology immunotherapy alongside its established biologic assets.
• Next Milestones: Completion of Phase I dose escalation; safety, PK and preliminary efficacy readouts. Timing not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, safety profile, efficacy potential and regulatory path of BA1203. Actual results may differ materially due to risks inherent in early‑phase oncology development, including dose‑limiting toxicities, immunogenicity, pharmacokinetic variability, and the possibility that preliminary efficacy signals do not persist in larger studies. A Phase I candidate may not progress to approval.-Fineline Info & Tech